LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
MELI
MercadoLibre, Inc.
MELI has the edge over LCID overall, supported by stronger valuation and lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MELI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Strong | |
| Stable |
MELI's revenue and cash flow are currently strong, and its profitability and balance sheet are stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
MELI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 33x | $1,475 | — |
| Current | 40x | $1,475 | — |
| Cheap | 50x | $1,874 | +27% |
| Fair | 75x | $2,798 | +90% |
| Expensive | 193x | $7,183 | +387% |
Historical ranges are pointers, not guarantees.
MELI's PE is in its cheap range at 40x. If earnings grow as analysts expect, today's price would be 33x next year's earnings.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MELI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MELI, but weaker profitability.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
MELI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $44.82 | +20% |
| Q3 2026 | $37.28 | -9% |
| Q2 2026 | $36.77 | -9.2% |
| Q1 2026 | $37.89 | -6.8% |
| Q4 2025 | $39.40 | +4.5% |
| Q3 2025 | $40.97 | +45% |
| Q2 2025 | $40.48 | +46% |
| Q1 2025 | $40.65 | +82% |
| Q4 2024 | $37.69 | +93% |
MELI has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID's revenue has grown year over year for 11 quarters in a row: $350M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
MELI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.8B | +45% |
| Q2 2026 | $10.2B | +50% |
| Q1 2026 | $8.8B | +49% |
| Q4 2025 | $8.8B | +45% |
| Q3 2025 | $7.4B | +39% |
| Q2 2025 | $6.8B | +34% |
| Q1 2025 | $5.9B | +37% |
| Q4 2024 | $6.1B | +42% |
MELI has the edge over LCID on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.3% | -3.5 points |
| Q2 2026 | 6.7% | -5.4 points |
| Q1 2026 | 6.9% | -5.9 points |
| Q4 2025 | 10% | -3.4 points |
| Q3 2025 | 9.8% | -0.7 points |
| Q2 2025 | 12% | -2.2 points |
| Q1 2025 | 13% | +0.7 points |
| Q4 2024 | 14% | +7.9 points |
MELI has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
MELI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4B | -6% |
| Q2 2026 | $3.2B | +22% |
| Q1 2026 | $1.8B | +138% |
| Q4 2025 | $4.8B | +83% |
| Q3 2025 | $2.6B | +89% |
| Q2 2025 | $2.6B | +55% |
| Q1 2025 | $759M | -44% |
| Q4 2024 | $2.6B | +50% |
MELI has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MELI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | 1.0x | Very low |
MELI's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MELI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 6.5 | Oversold |
MELI's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
MELI PE vs Consumer Cyclical Sector
| Metric | MELI | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 18x | 120% above |
| PE % | 0 | 47 | 47 pts below |
MELI is trading at 40x earnings, a 120% premium to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
MELI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,699.1 | 13% below |
| 20 week MA | $1,796.0 | 18% below |
| 50 week MA | $1,820.0 | 19% below |
| 100 week MA | $2,010.5 | 27% below |
| 200 week MA | $1,769.5 | 17% below |
MELI is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
MELI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $599.2 | $1,690.5 | +182% |
| 2021 | $1,690.5 | $1,262.7 | -25% |
| 2022 | $1,262.7 | $878.3 | -30% |
| 2023 | $878.3 | $1,571.5 | +79% |
| 2024 | $1,571.5 | $1,725.5 | +9.8% |
| 2025 | $1,725.5 | $2,005.7 | +16% |
| 2026 YTD | $2,005.7 | $1,475.1 | -26% |
MELI has the edge over LCID on returns for 2026, with the stronger performance.